Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F C Barone

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Molecular and Chemical Neuropathology|January 1, 1995
Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal strokeF C Barone, L M Hillegass, M N Tzimas, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 4, 2001
Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expressionS J Read, A A Parsons, D C Harrison, et al.
Stroke|September 1, 1995
SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and miceF C Barone, P G Lysko, W J Price, et al.
European Journal of Pharmacology|August 11, 2000
Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of strokeC A Campbell, F C Barone, C D Benham, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 1, 1997
The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemiaN I Wood, F C Barone, C D Benham, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Molecular and Chemical Neuropathology|January 1, 1995
Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal strokeF C Barone, L M Hillegass, M N Tzimas, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|July 4, 2001
Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expressionS J Read, A A Parsons, D C Harrison, et al.
Stroke|September 1, 1995
SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and miceF C Barone, P G Lysko, W J Price, et al.
European Journal of Pharmacology|August 11, 2000
Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of strokeC A Campbell, F C Barone, C D Benham, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|April 1, 1997
The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemiaN I Wood, F C Barone, C D Benham, et al.
Pageof 14